BRAXF - Braxia Scientific Faces Challenges In Accessing Public Market Capital Reports Q1 Loss | Benzinga
Braxia Scientific Corp. (OTC Pink: BRAXF), owner of ketamine therapy clinics and KetaMD telemedicine services for depression and related disorders, has shared its interim financial statements for the three months ended June 30, 2023.
In numbers:
-
Cash held was $636.483 (CA$861,393) as of June 30, compared to $1.08 million by March 31, 2023 and $5.67 million by June 30, 2022.
-
Quarterly revenue of $64.783, compared to $79.263 in the same period in 2022. Revenue’s 44% YoY increase ($443,490 vs. $308,490) was eclipsed by higher cost of sales ($378,707 now vs. $229,227 then.)
-
Quarterly operating expenses totaled $654.771, an almost 17% decrease from $783.859 in 2022’s comparable period.
-
Quarterly net loss of $592,785, around 18% down from the $715,878 net ...